Hormones To Prevent Coronary Disease in Women: When Are Observational Studies Adequate Evidence?
Authors: Deborah Grady
Journal: Annals of Internal Medicine (2000)

Editorials19 December 2000Hormones To Prevent Coronary Disease in Women: When Are Observational Studies Adequate Evidence?Deborah Grady, MD, MPH and Stephen B. Hulley, MD, MPHDeborah Grady, MD, MPHDrs. Grady and Hulley: University of California, San Francisco; San Francisco, CA 94105 and Stephen B. Hulley, MD, MPHDrs. Grady and Hulley: University of California, San Francisco; San Francisco, CA 94105Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-12-200012190-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail For many years, observational studies have reported that postmenopausal women who use estrogen have a lower rate of coronary heart disease than women who do not. Results of the Nurses' Health Study concerning this question were first published in 1985 (1) and were updated in 1991 (2), 1996 (3), and again in this issue (4). The main findings have not changed: Postmenopausal women who are current users of estrogen or estrogen plus a progestin have about a 40% lower risk for coronary disease compared with women who never used hormones. Many other observational studies have reported similar results (5), but ...References1. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-9. CrossrefMedlineGoogle Scholar2. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al . Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325:756-62. CrossrefMedlineGoogle Scholar3. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al . Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-61. CrossrefMedlineGoogle Scholar4. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-41. LinkGoogle Scholar5. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al . Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37. LinkGoogle Scholar6. . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273:199-208. CrossrefMedlineGoogle Scholar7. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-11. CrossrefMedlineGoogle Scholar8. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, et al . Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-7. CrossrefMedlineGoogle Scholar9. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-204. CrossrefMedlineGoogle Scholar10. Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke. 1994;25:814-20. CrossrefMedlineGoogle Scholar11. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13. CrossrefMedlineGoogle Scholar12. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al . Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-9. CrossrefMedlineGoogle Scholar13. Lenfant C. Statement from Claude Lenfant, MD, Director, National Heart, Lung, and Blood Institute, on preliminary trends in the Women's Health Initiative. National Heart, Lung, and Blood Institute Communications Office. 3 April 2000. Google Scholar14. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115:455-6. LinkGoogle Scholar15. Ettinger B, Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manag Care. 1999;5:779-85. MedlineGoogle Scholar16. . Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980;303:1038-41. CrossrefMedlineGoogle Scholar17. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. 1993;270:742-4. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Drs. Grady and Hulley: University of California, San Francisco; San Francisco, CA 94105Corresponding Author: Deborah Grady, MD, MPH, Department of Epidemiology, University of California, San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105.Current Author Addresses: Drs. Grady and Hulley: Department of Epidemiology, University of California, San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease Francine Grodstein , JoAnn E. Manson , Graham A. Colditz , Walter C. Willett , Frank E. Speizer , and Meir J. Stampfer Postmenopausal Hormone Therapy and Cardiovascular Disease Carsten Otto and Klaus Parhofer Alcohol and Congestive Heart Failure Ali Ahmed and Richard M. Allman Metrics Cited ByCaring for Patients in an Evidence-Limited WorldIs There a Personal Doctor in the House?Andrew B. Bindman, MDAntioxidant effects of equol on bovine aortic endothelial cellsThe HERACLES Cardiovascular NetworkRed cardiovascular HERACLESEffect of soy isoflavone protein and soy lecithin on endothelial function in healthy postmenopausal womenEstrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemiaThe Effect of Flax Seed Cultivars with Differing Content of α-Linolenic Acid and Lignans on Responses to Mental StressMolecular and Clinical Evidence for the Unique Nature of Individual Selective Estrogen Receptor ModulatorsBlood Pressure, Arterial Function, Structure, and Aging: The Role of Hormonal Replacement Therapy in Postmenopausal WomenAlcohol and Congestive Heart FailureAli Ahmed, MD, MPH and Richard M. Allman, MDEffects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulationDoes non-malignant hypertension cause renal insufficiency? Evidence-based perspectiveMotion: there is no relation between estrogen deficiency and cardiovascular morbidity. Some introductory remarks by the moderator Dr. Amos Pines to a debate between Dr. John Stevenson (for) and Dr. Trudy Bush (against)Postmenopausal Hormone Therapy and Cardiovascular DiseaseCarsten Otto, MD and Klaus Parhofer, MDThe Paired Availability Design for Historical ControlsSoy for Breast Cancer Survivors: A Critical Review of the LiteratureUpdate in EndocrinologyLeonard Wartofsky, MDHormone Replacement Therapy and Longitudinal Changes in Blood Pressure in Postmenopausal WomenAngelo Scuteri, MD, PhD, Angelo J.G. Bos, MD, PhD, Larry J. Brant, PhD, Laura Talbot, EdD, PhD, Edward G. Lakatta, MD, and Jerome L. Fleg, MDPostmenopausal hormone therapy and primary prevention of cardiovascular disease — Nurses' health study 20-year follow-upThe Nurses' Health Study: unresolved issues after 20-years follow-upThe Queen… is naked!Hormone Replacement Therapy in Primary and Secondary Prevention of Coronary Artery Disease: Cardiologist and Geriatric Specialist PerspectivesPostmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?Homocysteine and atherothrombosisEvidence-Based Medicine and GeriatricsHormone Replacement Therapy – The Silver Bullet That MisfiredThe Cohort Study – Watchful Waiting 19 December 2000Volume 133, Issue 12Page: 999-1001KeywordsCoronary heart diseaseEstrogen replacement therapyEstrogensHormonal therapyHormonesIschemic strokeLipidsObservational studiesRandomized trialsTreatment guidelines ePublished: 19 December 2000 Issue Published: 19 December 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...